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Abstract
Background: P21
(WAF1/Cip1) binds to cyclin-dependent kinase complexes and inhibits their activities. It was
originally described as an inhibitor of cancer cell proliferation. However, many recent studies have shown that p21
promotes tumor progression when accumulated in the cell cytoplasm. So far, little is known about the correlation
between cytoplasmic p21 and drug resistance. This study was aimed to investigate the role of p21 in the cisplatin
resistance of ovarian cancer.
Methods: RT-PCR, western blot and immunofluorescence were used to detect p21 expression and location in
cisplatin-resistant ovarian cancer cell line C13* and its parental line OV2008. Regulation of cytoplasmic p21 was
performed through transfection of p21 siRNA, Akt2 shRNA and Akt2 constitutively active vector in the two cell
lines; their effects on cisplatin-induced apoptosis were evaluated by flow cytometry. Tumor tissue sections of
clinical samples were analyzed by immunohistochemistry.
Results: p21 predominantly localizes to the cytoplasm in C13* compared to OV2008. Persistent exposure to low
dose cisplatin in OV2008 leads to p21 translocation from nuclear to cytoplasm, while it had not impact on p21
localization in C13*. Knockdown of cytoplasmic p21 by p21 siRNA transfection in C13* notably increased cisplatin-
induced apoptosis through activation of caspase 3. Inhibition of p21 translocation into the cytoplasm by
transfection of Akt2 shRNA into C13* cells significantly increased cisplatin-induced apoptosis, while induction of
p21 translocation into the cytoplasm by transfection of constitutively active Akt2 in OV2008 enhanced the
resistance to cisplatin. Immunohistochemical analysis of clinical ovarian tumor tissues demonstrated that
cytoplasmic p21 was negatively correlated with the response to cisplatin based treatment.
Conclusions: Cytoplasmic p21 is a novel biomarker of cisplatin resistance and it may represent a potential
therapeutic target for ovarian tumors that are refractory to conventional treatment.
Background
Ovarian cancer is the sixth most common cancer among
women and it leads to the highest mortality per year
than any other cancers of the female reproductive sys-
tem [1,2]. Cisplatin derivatives are first-line chemothera-
peutic agents used for treatment of ovarian cancer.
However, chemoresistance remains a major hurdle to
successful therapy and results in low five-year survival
rates [2,3]. Previous studies have suggested that resis-
tance may be due to reduced drug accumulation [4],
increased levels of glutathione and metallothionein [5]
and enhanced DNA repair [6]. At present, it is widely
accepted that the apoptotic response of cancer cells to
chemotherapeutic drugs is the determining force for
sensitivity to chemotherapy [7,8]. Many molecules,
including XIAP [3], MKP3 [9], PI3K, Akt2 [10,11],
PTEN [12], P-glycoprotein [13] and MDR [14], have
been reported to be involved in the regulation of apop-
tosis and in the complicated signaling network that
determines the fate of cancer cells, i.e., either “death” or
“survival.” Though much progress has been made, our
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of cancer cells to chemotherapeutic agents before treat-
ment and to identify the possible alterations that med-
iate resistance.
P21 was the first identified inhibitor of cyclin/cyclin-
dependent kinase (CDK) complexes [15]. Previous stu-
dies demonstrated that p21 could act as a “tumor sup-
pressor” by binding to cellular CDK and proliferating
cell nuclear antigen (PCNA), thereby inhibiting their
function and leading to cell cycle arrest, leading to
blockade of DNA synthesis and inhibition of cell prolif-
eration [15,16]. Numerous studies that analyzed the
expression of p21 in different types of human cancers
have revealed that loss of p21 correlates with carcino-
genesis and a poor prognosis in small-cell lung, colorec-
tal, cervical and head and neck cancers [17-20]. In
contrast, other findings have found that increased p21
expression was associated with tumor progression in
ovarian, cervical, breast and esophageal squamous cell
carcinomas [21-26]. This discrepancy could be due to
the status of p21 itself and/or to differences in the histo-
logical types of cancers that have been analyzed. Besson
et al. [27] suggested that control of the subcellular loca-
lization of p21 could represent an important regulatory
switch from a nuclear tumor suppressor to a cytoplas-
mic oncogene. Once phosphorylated by Akt, p21 is
induced to emigrate from the nucleus to the cytoplasm,
protecting cells from apoptosis [28-31]. Additionally,
clinical immunohistochemical analysis have proven that
cytoplasmic p21 is a novel predictor of poor prognosis
in breast cancer [32,33]. Although the role of p21 in the
development of various types of human cancers has gar-
nered much attention, little is known about its involve-
ment in drug resistance.
Given that chemoresistance is a biological trait of
tumor malignancy and has a direct influence on a
patient’s prognosis, this study was designed to explore
whether cytoplasmic p21 correlated with cisplatin resis-
tance in ovarian tumors. In addition, we sought to
determine whether interfering with cytoplasmic p21
could enhance the susceptibility of cancer cells to cispla-
tin. Here, we report that in the cisplatin-resistant cell
line C13*, p21 is predominantly localized to the cyto-
plasm, while in the cisplatin-sensitive cell line OV2008,
p21 is mainly restricted to the nucleus. Additionally, the
exposure to low-dose cisplatin in OV2008 induced
translocation of most p21 protein from nuclear to cyto-
plasm. Knockdown of cytoplasmic p21 by transfection
of p21 siRNA into C13* cells notably enhanced their
sensitivity to cisplatin. Inhibition of p21 translocation
into the cytoplasm by Akt2 shRNA transfection in C13*
cells significantly enhanced their sensitivity as well. Con-
versely, the accumulation of p21 in the cytoplasm by
transfection of active Akt2 in OV2008 conferred
resistance to cisplatin in OV2008 cells. Further analysis
of clinical ovarian tumor samples by immunohistochem-
istry revealed that p21 was predominantly localized in
the nucleus in the drug sensitive group. In contrast, p21
is mainly localized in the cytoplasm in the drug resistant
group.
Methods
Cell lines and cell culture
The cisplatin-resistant ovarian cancer cell line C13* and
its parental variant OV2008 were provided by Doctor
Benjamin K. Tsang (Department of Obstetrics, Gynecol-
ogy and Cellular and Molecular Medicine, University of
Ottawa, Canada). Cells were maintained in RPMI-1640
supplemented with 2 mM L-glutamine, 100 U/ml peni-
cillin, 100 mg/ml streptomycin and 10% fetal bovine
serum (FBS) at 37°C in a humidified atmosphere con-
taining 5% CO2.
Clinical samples
From 2004 through 2007, 40 patients who were diag-
nosed with ovarian carcinoma and received standard cis-
platin-based intravenous chemotherapy after surgery at
Tongji Hospital, Tongji Medical College, Huazhong Uni-
versity of Science and Technology were included in the
study after obtainment of oral and written informed
consents. Paraffin-embedded tumor tissue sections of
each patient were prepared by the Department of Clini-
cal Pathology. Information on histopathologic diagnosis
was extracted from medical records and reviewed by a
specialist in gynecologic pathology. The patients were
selected and divided into treatment response and treat-
ment non-response groups according to the CA125 cri-
teria proposed by the Gynecological Cancer Intergroup
(GCIC) [34]. Briefly, treatment response patients were
defined as having at least a 50% reduction in CA125
levels, when compared to pretreatment samples, and
this reduction must have been maintained for at least 28
days; the intervening value of CA125 must have been
less than or equal to the previous value. Patients
demonstrated any clinical evidence of progression, such
as increased lump size and ascites, were excluded from
the treatment response group. The remaining patients
were classified as treatment non-response group. This
study was reviewed and approved by the ethics commit-
tee of the medical faculty at the Tongji Hospital, Tongji
Medical College, Huazhong University of Science &
Technology.
Antibodies and reagents
Antibodies against Akt, Ser473-phosphorylated Akt and
p21 were purchased from Cell Signaling Technology,
Inc. (Beverly, MA, USA). b-actin antibody and second-
ary goat anti-rabbit and goat anti-mouse alkaline
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Biotechnology (Santa Cruz, CA, USA). Anti-caspase 3
antibody was purchased from Biolegend Co. (San Diego,
CA, USA). RPMI-1640, FBS, Lipofectamine 2000 and
Trizol reagent were purchased from Invitrogen Co.
(Carlsbad, CA, USA). Cisplatin, MTT, DMSO, G418 and
DAPI dye were obtained from Sigma Chemical Co. (St.
Louis, MO, USA). The NE-PER cytoplasmic protein
extraction kit was purchased from Pierce Co. (Rockford,
IL, USA). The annexin-V/PI apoptosis detection kit was
purchased from Promoter Biotech Ltd. (Wuhan, Hubei,
China).
Construction of plasmids
A constitutively active Akt expression vector (AAkt2)
and short hairpin RNA targeting Akt2 (Akt2Sh) were
described previously [11,35]. The sequences of the p21
RNA interfering fragment (p21si) were as follows: sense,
5’- CUU CGA CUU UGU CAC CGA G -3’;a n t i - s e n s e ,
5’- C UCG GUG ACA AAG UCG AAG -3’ [36]. The
sequences of the mismatched fragment (p21sm) were:
sense, 5’- CUC GAC UUC GUA CCC GAG -3’:a n t i -
sense, 5’- CUC GGG UAC GAA GUC GAG -3’.
Transient transfection for RNAi targeting
For RNAi targeting, C13* cells cultured in 6-well plates
were transfected with indicated plasmids using Lipofec-
tamine 2000. After 6 hours of incubation, the transfec-
tion solution was removed, and was replaced with fresh
complete growth medium. 48 hours post-transfection
the cells were assayed for the expression of p21 and
treated with cisplatin for further experiment.
Establishment of stable-expression cell lines of AAkt2 in
OV2008 cells and Akt2sh in C13* cells
OV2008 cancer cells were stably transfected with AAkt2
vector, C13* cancer cells were stably transfected with
Akt2sh, using Lipofectamine 2000. Their corresponding
empty vectors, i.e., pcDNA3.1 and pEGFPC1, were
transfected as negative control. The cells were selected
with G418. The concentration of G418 for selection and
maintenance was 600 μg/μl. After three weeks the
G418-resistant cell pools were established and seeded
into 100 mm dishes for further propagation.
Real-time PCR
Total RNA was isolated from each group of cells using
Trizol Regent, according to the manufacturer’si n s t r u c -
tion. Real-time PCR amplifications were carried out
using DNase I (Promega)-treated total RNA. Reactions
were performed in a Stratagene MX3000P system using
the Real-time PCR Master Mix (TOYOBO, Japan). P21
primer sequences were as follows: sense, 5’-CCT CTT
CGG CCC GGT GGA C-3’:a n t i - s e n s e ,5 ’-CCG TTT
TCG ACC CTG AGA G-3’. GAPDH primer sequences
were as follows: sense, 5’-ACG GAT TTG GTC GTA
TTG GG-3’; anti-sense, 5’-TGA TTT TGG AGG GAT
CTC GC-3’.
Western blot analysis
Total proteins were extracted by lysing cells in buffer
containing 50 mM Tris pH 7.4, 150 mM NaCl, 0.5% NP-
40, 50 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsul-
fonyl fluoride, 25 mg/ml leupeptin and 25 mg/ml aproti-
nin. The lysates were cleared by centrifugation, and the
supernatants were collected. Cytoplasmic proteins were
extracted using the N-PER cytoplasmic protein extraction
kit according to manufacturer’s instructions. Equal
amounts of protein lysate were used for western blot ana-
lyses. Specific signals were visualized with NBT/BCIP.
Cell viability assay using MTT
Cells were seeded into 96-well plates, treated with dif-
ferent concentrations of cisplatin for 24 hours and then
assessed using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphe-
nyltetrazolium bromide. Cell viability was determined by
measuring the optical absorbance of cells at 570 nm
wavelength and normalizing the values to the corre-
sponding controls.
Analysis of apoptosis by flow cytometry
Cells were harvested, washed with PBS and stained with
the annexin-V/PI apoptosis kit according to manufac-
turer’s instructions. Analysis of apoptotic cells was per-
formed using a FACScan flow cytometer, and the data
were analyzed using cell fit software.
Immunofluorescence
Cells were trypsinized and plated onto chamber slides for
12 hours. After fixation in acetone, the slides were blocked
with BSA, incubated with p21 antibody and rhodamine-
conjugated secondary antibody and counterstained with
DAPI. Slides were then observed on a confocal laser-scan-
ning microscope (Olympus IX81, Japan). P21 staining was
categorized as negative, nuclear or cytoplasmic according
to a standard described before [32]. Briefly, negative was
defined as undetectable cytoplasmic or nuclear staining.
Nuclear p21 was defined as the fraction of tumor cells
with positive nuclear staining greater than or equal to that
of positive cytoplasmic staining. Cytoplasmic p21 was
defined as the fraction of cytoplasmic staining greater than
that of nuclear staining. Five randomized fields were
counted in order to calculate the percentage of cells that
stained with anti-p21 antibody.
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized.
After antigen retrieval, slides were incubated with 3%
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then blocked with 5% normal serum and incubated with
anti-p21 antibody. For qualitative identification of speci-
fic antibody staining, the DAKO Envision+ system was
used, according to manufacturer’s instructions, as
described below. After detection with chromogen diami-
nobenzidine, sections were counterstained with hema-
toxylin and mounted. For the negative control, all
incubation steps were identical except that PBS was
used instead of primary antibody. The immunoreactivity
of p21 was categorized as negative, nuclear or cytoplas-
mic according to the standard decribed before [32].
Image analysis
Western blot images were captured and quantified using
the ChemiImager 5500 system from the Alpha Innotech
Corporation (San Leandro, CA, USA).
Statistical analysis
All experiments were repeated three times. The relation-
ship between patients’ clinical characteristics and results
of p21 immunohistochemistry was assessed using the
chi-squared (c
2) test. Results expressed as mean ± SD
were analyzed using the Student t test. Differences were
considered significant when p < 0.05. Data were ana-
lyzed using SPSS software version 13.0 (SPSS Inc., Chi-
cago, IL).
Results
Cisplatin-induced cytotoxicity and apoptosis in resistant
and sensitive cell lines
The MTT assay was used to examine the effects of cis-
platin on the proliferation of C13* and OV2008 cells.
The cells were exposed to different doses of cisplatin for
2 4h o u r s .A ss h o w ni nF i g u r e1 A ,c i s p l a t i nd e c r e a s e d
the viability of both C13* and OV2008 cells in a dose-
dependent manner. However, OV2008 cells were more
sensitive to cisplatin, exhibiting an approximately 6-fold
greater decrease in viability than C13* cells, as evaluated
by the IC50 value (p < 0.05). The difference between cis-
platin-induced viability inhibition of the two cell lines
peaked at 51.9% with 20 μM cisplatin (p < 0.05). By
flow cytometry, we observed that cisplatin treatment
increased apoptosis of OV2008 and C13* cells in a time-
dependent manner (Figure 1B). After 24 hours of expo-
sure to cisplatin, there was at least a 2-fold increase of
apoptotic OV2008 cells when compared to C13* cells.
Cytoplasmic p21 is more abundant in resistant cells than
in sensitive cells
Expression of p21 was examined by real-time PCR and
western blot in the paired cell lines. There was no sig-
nificant difference in the levels of p21 mRNA and total
protein between the two cell lines (Figure 1C and 1D).
T h er e s u l to fr e a l - t i m eP C Rw a sn o r m a l i z e dt ot h e
expression of GAPDH. The density of individual bands
from western blot results were quantified and the ratios
of C13* to OV2008 were calculated. The ratios of C13*
to OV2008 in real-time PCR and western blot were 0.99
and 1.05, suggesting that C13* and OV2008 cells had
equal expression levels of p21 (Figure 1D) (p > 0.05). By
comparing cytoplasmic protein levels, we found that the
amount of cytoplasmic p21 was much higher in C13*
cells than in OV2008 cells (Figure 1C). The relative den-
sities of the western blot bands shown in Figure 1C
were calculated and the value was shown in Figure 1D.
T h er e s u l t sd e m o n s t r a t et h a tC 1 3 *c e l l sh a v ea3 . 3 1( ±
0.33)-fold higher level of cytoplasmic p21 than do
OV2008 cells (p < 0.05). We used immunofluorescence
and confocal microscopy to further validate these differ-
ences and found that in C13* cells p21 was predomi-
nantly located in cytoplasm (Figure 2A, upper panels),
while in OV2008 cells p21 was mainly restricted in the
nucleus (Figure 2A, upper middle panels). In addition,
we determined the percentage of cytoplasmic p21 in
C13* and OV2008 cells. As shown in Figure 2B, we
found that in C13* cells 88.1% ± 3.45% of p21 was
found in the cytoplasm, while in OV2008 cells 25.2% ±
4.8% of p21 was cytoplasmic (p < 0.05).
Persistent exposure to low dose cisplatin induces p21
translocation into cytoplasm in sensitive cells
To examine the effect of cisplatin on p21, OV2008 and
C13* cells were consecutively treated with low-dose of 5
μM cisplatin. Three weeks later, immunofluorescence
and confocal microscopy were applied to detect p21’s
Figure 1 Cisplatin-induced cytotoxicity and apoptosis, and
expression of p21 in C13* and OV2008 cells. (A) Dose-response
curves for C13* and OV2008 cells following treatment with cisplatin.
(B) Cisplatin-induced apoptosis at different time points (20 μM). (C)
Comparison of p21 protein levels between paired cell lines. (D) The
p21 expression ratio of C13* to OV2008 cells. (*, p < 0.05).
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with cisplatin 66.6% ± 5.96% of p21 was found in the
cytoplasm (Figure 2A, lower panels), which was dramati-
cally higher than in OV2008 cells not treated with cis-
platin (Figure 2B) (p < 0.05). However, in C13* cells no
obvious changes of p21 sub-cellular location was
observed after treatment with cisplatin (Figure 2A, lower
middle panels). The percentage of cytoplasmic p21 in
C13* cells that were exposed to cisplatin was 87.9% ±
5.22%, which was equal to parental control (Figure 2B)
(p > 0.05). By measurement of western blot, the amount
of cytoplasmic p21 was notably enhanced after treating
with cisplatin in OV2008 (Figure 2C). However, there
was no significant elevation in cytoplasmic p21 protein
in C13* cells after treating with cisplatin (Figure 2C).
Knockdown of cytoplasmic p21 restores the sensitivity to
cisplatin in C13*
To determine whether cytoplasmic p21 contributes to
cisplatin resistance, RNA interference assay in C13* was
applied to suppress p21 that was mainly in the cyto-
plasm. C13* cells were transiently transfected with p21si
and its mismatched fragment of p21sm. By western blot,
p21si transfection exhibited a dramatic decrease in cyto-
plasmic p21 compared with control groups (Figure 3A).
After transfection, these cells were exposed to different
concentrations of cisplatin for 48 hours. As shown in
Figure 3B, the apoptosis rates in both C13*/p21sm and
C13*/p21si exhibited a concentration-dependent man-
ner. The rates in p21si group were notably higher than
their counterparts in mismatch-transfected group (p <
0.05). In the meantime, the effect of cytoplasmic p21 on
cisplatin sensitivity was examined by caspase 3 activa-
tion. Using western blot, we found the level of cleaved
caspase 3 protein in p21si group was significantly higher
than its control groups (Figure 3C). These data indicate
the reduction of cytoplasmic p21 endows cisplatin-resis-
tant cells with increased sensitivity through activation of
caspase 3.
Inhibition of p21 translocation into cytoplasm enhances
the sensitivity to cisplatin in C13*
Expression of Akt and p-Akt was examined by western
blot in the paired cell lines. As shown in additional file
1, Figure S1, the protein level of p-Akt in C13* was
markedly higher than in OV2008, while there was no
significant difference in the Akt protein between the
two cell lines. Short hairpin RNA targeting Akt2 was
stably transfected into C13* cells. Total and cytoplasmic
protein was extracted and analyzed by western blot. In
contrast to control cells, the protein levels of Akt and p-
Akt were significantly decreased in Akt2Sh transfected
cells. In addition, cytoplasmic p21 was remarkably
decreased following RNA silencing of Akt2 (Figure 4A).
Figure 2 Cellular distribution of p21 in C13* and OV2008 cells
and its alteration after 3-week of continuous cisplatin
treatment. (A) Localization of p21 in C13* (upper panels), OV2008
(upper middle panels), C13*/DDP (lower middle panels) and
OV2008/DDP (lower panels) cells. (B) Percentage of cytoplasmic p21
positive cells. (C) Comparison of cytoplasmic p21 between C13* and
C13*/DDP, and between OV2008 and OV2008/DDP. (*, p < 0.05; **,
p < 0.01).
Figure 3 Knockdown of cytoplasmic p21 in cisplatin-resistant
cells enhances apoptosis rate to cisplatin. (A) Representative
western blot demonstrating the changes in cytoplasmic p21 protein
levels observed in C13*/control, C13*/p21si and C13*/p21sm cells.
(B) Apoptosis rates in response to cisplatin. (C) Corresponding
western blot images of each group of cells depicted in A showing
changes in cleaved caspase 3. (*, p < 0.05).
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platin for 48 hours demonstrated that C13* cells trans-
fected with Akt2 exhibited 33.6% ± 2.7% apoptosis rate,
which was higher than non-transfected control cells
(21% ± 4.4%) and vector-transfected cells (21.1% ± 4.2%)
(p < 0.05, Figure 4C). Collectively, these results demon-
strate that inhibition of cytoplasmic p21 through inacti-
vation of Akt2 restores sensitivity of resistant ovarian
cells to cisplatin.
Induction of p21 translocation into the cytoplasm
decreases sensitivity to cisplatin in OV2008
The plasmid of AAkt2 was stably transfected into
OV2008 cells. Total and cytoplasmic protein was
extracted from the cells and analyzed by western blot.
The protein levels of Akt and p-Akt were significantly
increased in AAkt2 cells when compared to control cells
(Figure 4B). Moreover, cytoplasmic p21 protein levels
were markedly enhanced in AAkt2 transfected cells
when compared to control cells (Figure 4B). Flow cyto-
metric analysis of cells exposed to 20 μMc i s p l a t i nf o r
48 hours demonstrated that OV2008 cells transfected
with AAkt2 exhibited lower levels of apoptosis (33.6% ±
4.0%) than did non-transfected control cells (52% ±
5.1%) and vector-transfected cells (53.3% ± 3.4%) (p <
0.05, Figure 4D). These results show that accumulation
of p21 in cytoplasm by activation of Akt2 impairs the
susceptibility of sensitive ovarian cells to cisplatin.
Expression of p21 in the cytoplasm is associated with
cisplatin response in clinical samples
Based on the results of our in vitro experiments, we
decided to examine whether cytoplasmic p21 expression
can serve as a marker for cisplatin resistance in ovarian
cancer patients. Histological sections of ovarian cancer
tissues were examined by immunohistochemistry for
p21. The patients’ clinical characteristics and results of
p21 immunohistochemistry were shown in Table 1. The
number of patients with cytoplasmic and non-cytoplas-
mic p21 staining was 5 and 8 in the non-response
group. However, in the response group, 2 and 25
patients were cytoplasmic and non-cytoplasmic respec-
tively. These findings indicated that the proportion of
cytoplasmic p21 staining was significantly higher in
non-response group than in response group (p = 0.027).
Representative images of immunohistochemistry were
shown in Figure 5, which demonstrated that p21 was
predominantly localized in the cytoplasm in the non-
response patient group (Figure 5A). In contrast, p21 is
mainly localized in the nucleus in response group (Fig-
ure 5C). Additionally, cytoplasmic p21 staining was eval-
u a t e di np a t i e n t sa td i f f e r e n tclinical stages. In patients
at stages III & IV, the number of patients with
Figure 4 Inhibition of p21 translocation into cytoplasm
enhances the sensitivity to cisplatin in C13*, while induction of
p21 translocation into the cytoplasm results in increased
resistance to cisplatin in OV2008. (A) Representative western blot
images showing the changes in Akt, p-Akt and cytoplasmic p21 in
C13*. (B) Representative western blot images showing the changes
in Akt, p-Akt and cytoplasmic p21 in OV2008. (C) Apoptosis rates of
C13* cells in response to cisplatin. (D) Apoptosis rates of OV2008
cells in response to cisplatin. (*, p < 0.05).
Table 1 Association of cytoplasmic p21 with
clinicopathological parameters (n = 40)
Characteristics Total p21’s expression P#
Cytoplasmic Nuclear/
Negative
Age ≤ 50 23 5 16/2 .677
> 50 17 2 14/1
Histology* Serous 20 2 17/1 .407
Mucous 8 1 6/1
Others 8 3 5/0
Stage I & II 15 2 13/0 .691
III & IV 25 5 17/3
Cisplatin Response 27 2 23/2 .027
Non-
response
13 5 7/1
* Four patients are not available; P values are calculated by Fisher exact test.
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20, respectively. In patients at stages I & II, 2 patients
exhibited cytoplasmic p21 staining, and 13 patients
exhibited noncytoplasmic p21 staining (p = 0.691). This
result suggested that there was no significant difference
in the percentage of patients with cytoplasmic p21 stain-
ing between high stage and low stage ovarian tumors.
Similarly, there was no significant difference in the levels
of cytoplasmic p21 staining between serous and non-
serous tumors (p = 0.407) or between groups of differ-
ent ages (p = 0.677).
Discussion
It is well known that p21
(Waf1/Cip1) in the nucleus func-
tions as a tumor suppressor by binding to cyclin/CDK
complexes and proliferating cell nuclear antigen [15,16].
However, recent studies [31,32] have revealed that p21
can be a paradoxical tumor promoting factor and has
been associated with poor cancer prognosis due to its
accumulation in the cytoplasm. Recently, Koster has
reported cytoplasmic p21 expression levels determined
cisplatin resistance in testicular cancer [37]. This study
was aimed at exploring the relationship between cyto-
plasmic p21 and cisplatin resistance in ovarian cancer,
and investigating whether regulation of cytoplasmic p21
could alter the response to the therapy.
The cisplatin-resistant cell line C13* used in this study
was established after in vitro challenge of OV2008 cells,
a line derived from one ovarian carcinoma patient with-
out prior chemotherapy, with cisplatin [38,39]. Since
C13* and OV2008 cells shared the same genetic back-
ground and had minimum variation, they were superior
to other cell lines and were chosen as optimal models
for in vitro investigation of drug resistance. After con-
firming the expression levels and cellular distribution of
p21 in the paired cell lines, we sought to determine
whether it was influenced by cisplatin treatment and
whether it was involved in cisplatin resistance. Long-
term exposure to low-dose cisplatin resulted in p21
cytoplasmic translocation in cisplatin-sensitive cells,
while the same treatment nearly had no effect on p21
cellular distribution in cisplatin-resistant cells. These
results suggested p21’s accumulation in cytoplasm was
probably a protective response of sensitive cells to the
drug, which helped them to escape from being killed by
chemotherapeutics. Given that the endogenous p21 pro-
tein in resistant cells was mainly located in the cyto-
plasm, loss-of-function assay of cytoplasmic p21 was
directly taken by RNA interference technology. Our
results indicated knockdown of cytoplasmic p21 through
p21 siRNA notably enhanced drug response in C13*
cells. However, p21 transfection might not be the suita-
ble strategy to illustrate the influence of increased cyto-
cymic p21 because endogenous p21 in OV2008 was
mainly restricted in the nuclear; The exogenous p21
transfected into OV2008 would probably mainly
increase the nuclear amount instead of cytoplasmic
amount. Thus, we increased the amount of cytoplasmic
p21 by promoting its translocation from nuclear to cyto-
plasm in sensitive cells.
Zhou et al. reported that activation of phosphatidyli-
nositol 3-kinase (PI3K)/Akt signaling can stimulate cyto-
plasmic accumulation of p21 [29]. There are three
isoforms of Akt: Akt1, Akt2 and Akt3. All three iso-
forms share a high degree of amino acid sequence iden-
tity, especially within the kinase domain [40], and are
activated by similar pathways in a PI3K-dependent man-
ner. Overexpression of Akt2 has been found in 20% of
human ovarian cancers [41], and increased Akt2 kinase
activity has been found in approximately 30% of ovarian
cancers [42]. Given these findings, we performed experi-
ments where we altered the levels of cytoplasmic p21 by
modulating Akt2 signaling. In OV2008 cells, a constitu-
tively active AAkt2 plasmid was applied to activate
PI3K/Akt signaling. Our results showed that the AAkt2
plasmid efficiently activated phosphorylation of Akt and,
more importantly, significantly promoted the transloca-
tion of p21 into the cytoplasm. In the meantime, func-
tional inhibition of cytoplasmic p21 was accomplished
by short hairpin RNA silencing of Akt2 in C13* cells.
Nevertheless, in fibroblasts and myoblasts, it has been
suggested that the accumulation of p21 in the cytoplasm
is stimulated by Akt1 [43]. The differences in our results
might be ascribed to the different cell types used in the
Figure 5 Representative immunohistochemical staining for p21
and H&E analysis of tissues from treatment non-response
(upper panels) and treatment response (lower panels) patients.
(A) Representative image of p21 expression in tissues from a
treatment non-response patient. (B) H&E staining of a sequential
section from the sample shown in A. (C) Representative image of
p21 expression in tissues from a treatment response patient. (D)
H&E staining of a sequential section from the sample shown in C.
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mutual activation of the different isoforms. Therefore,
the role of different Akt isoforms in the cytoplasmic
translocation of p21 requires further investigation.
Caspase 3 activation is considered to be a key cellular
component of the terminal and irreversible phase of
apoptotic death caused by DNA damaging agents. In
our experiments using flow cytometry, we found that
the levels of cleaved caspase 3 (17 kDa) were propor-
tional to the rate of apoptosis. Previously, it was
reported that p21 could bind to procaspase 3 [31] and
prevent its conversion to mature caspase 3, leading to
the inhibition of apoptosis. In our experiments, it is
likely that caspase 3 activation is inhibited by cytoplas-
mic p21; however, further studies are required to con-
firm this hypothesis.
By immunohistochemical analysis we found that a large
proportion of tissues from treatment non-response
tumors stained positive for cytoplasmic p21 (5 to 8)
when compared to tissues from the treatment response
group (2 to 25) (p = 0.027). We also showed that there
was no significant difference in the level of cytoplasmic
p21 staining between high stage and low stage ovarian
tumors (p = 0.691), and between patients of different
ages (p = 0.677). Furthermore, we compared cytoplasmic
p21 levels in serous and non-serous tumors because the
number of mucous and other types of tumors was lim-
ited. However, information on the prognosis and survival
of the patients was not available; therefore, our investiga-
tion could not make a statistical analysis between cyto-
plasmic p21 and disease-free or survival rates.
Conclusions
Our in vitro experiments demonstrate cytoplasmic p21
is a novel biomarker in cisplatin resistance, and regula-
tion of cytoplasmic p21 could alter the response of ovar-
ian tumor cell lines to the drug. This finding
supplements our previous studies [11,12,34] and verifies
that p21 is a downstream effector in the PI3K/Akt2
pathway that contributes to drug resistance.
Additional material
Additional file 1: Figure S1. Representative western blot depicting the
Akt and p-Akt protein levels between C13* and OV2008 cells. Total
protein was extracted from C13* and OV2008, and western blot was
applied to compare the Akt and p-Akt expression between the paired
cell lines.
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